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S174 Oral Presentationsas well as regulatory T cells and are therefore of great interest for
post-transplant immunotherapy. Human B cells when activated via
CD40-L/IL-4 can be expanded from small amounts of peripheral
blood in 12-14 days. CD40-activated B cells can prime naı¨ve T cells,
expand memory T cells and express important surface homing mol-
ecules. Nevertheless, it remains unclear whether such cells have the
property to attract and interact withT cells in a physiological context
and whether CD40-activated B cells migrate to secondary lymphoid
organs (SLO) in vivo, a necessary step for an antigen-presenting cell
(APC) to induce immunity. To address this question we established
a platform to generate murine CD40-activated B cells. At day 14 of
culture, these cells are .95% CD19+ and CD80/86/MHCI/
MHCIIhi.Murine CD40-activated B cells present a ‘homing pheno-
type’; migrate towards SLO chemokines such as CCL19, CCL21
and CXCL13; and induce T-cell chemotaxis in vitro. Upon
CD40L activation, B cells up-regulate CCR7 while down-regulate
CXCR5 expression which suggests direction of activated B cells
towards the B-zone-T-zone boundary. We compared the homing
of GFP+ CD40-activated B cells to resting GFP+ B cells and
show for the first time that CD40-activated B cells home to SLO
significantly more efficiently than resting B cells. Furthermore,
CD40-activated B cells localize in B-cell areas, and a significant frac-
tion move to the B-T boundary close to the T-cell zone. To dissect
T-cell-APC interactions on a single cell we analyzed three-dimen-
sional migration in collagen matrix. Interestingly, antigen-loaded
CD40-activated B cells differ from immature andmature DC by dis-
playing a rapid migratory pattern undergoing highly dynamic, short-
lived (7.5 min) and sequential interactions with cognate T cells.
Taken together, these data reveal that CD40-activated B cells can
home to secondary lymphoid organs and interact dynamically with
T cells thus underlining their potential as cellular adjuvant for cancer
immunotherapy.53
MULTIVIRUS-SPECIFIC T CELL IMMUNOTHERAPY TO PREVENT OR
TREAT INFECTIONS OF ALLOGENEIC STEM CELL TRANSPLANT RECIPI-
ENTS
Leen, A.M., Gerdemann, U., Christin, A., Ramos, C.A., Heslop, H.E.,
Brenner, M.K., Rooney, C.M., Vera, J.F. Baylor College of Medicine,
The Methodist Hospital, Texas Children’s Hospital, Houston, TX
Viral infections causemorbidity andmortality in allogeneicHSCT
recipients. We and others have successfully generated and infused
adoptive T-cell lines specific for EBV, CMV and Adenovirus using
monocytes and EBV-transformed lymphoblastoid cell (EBV-LCL)
gene-modified with an adenovector as antigen presenting cells
(APCs). We have shown that as few as 2105/kg trivirus-specific
cytotoxic T lymphocytes (CTL) proliferated by several logs post-
infusion and appeared to prevent and treat even severe viral disease
resistant to other available therapies.Despite the encouraging clinical
results, broader implementation of this ‘‘trispecific’’ CTLapproach is
limited by high production costs, complexity of manufacture and the
prolonged time (4-6 weeks for EBV-LCL generation, and 6-8 weeks
for CTL manufacture – total 10-14 weeks) for preparation.
To overcome these manufacturing limitations we have developed
new, GMP-compliant strategies. In place of adenovectors we now
use DCs nucleofected with non-viral DNA plasmids encoding
LMP2 and BZLF1 (EBV), Hexon and Penton (Adv), pp65 (CMV)
and Large T antigen (BK virus) to stimulate T-cells. Furthermore,
by pooling nucleofected DCs prior to PBMC stimulation, we can
reproducibly generate multivirus-specific CTL lines reactive against
all the stimulating antigens, without discernible antigenic competi-
tion. Secondly, we have demonstrated that the culture of activated
T-cells in the presence of IL-4 (1,000U/ml) and IL-7 (10ng/ml) pro-
motes the survival of both high and low frequency antigen-specific
CTL and sustains the breadth of reactivity in our lines. Finally, we
have replaced traditional plastic cultureware with a new, gas perme-
able culture device (G-Rex) which promotes the expansion and
survival of large cell numbers in a closed systemwithminimal techni-
cian intervention. By implementing these changes we can now pro-
duce multispecific CTL targeting EBV, CMV, Ad, and BK virus at
a cost per 106 cells that is reduced by.90%, and in just 10 days rather
than 10 weeks using an approach that may be extended to additional
protective viral antigens. Our approach should be of value for pro-phylactic and treatment applications for high risk allogeneic HSCT
recipients.54
FAST B- AND NK-, RECONSTITUTION EARLY AFTER UNRELATED CORD
BLOOD TRANSPLANTATION COMPARED TO (UN)RELATED BONE MAR-
ROW TRANSPLANTATION IN CHILDREN
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Early immune reconstitution after allogeneic-haematopoietic
stem cell transplantation (HSCT) is important for controlling
infectious complications. We compared T-, B- and NK-cell recon-
stitution during the first 100 days after bone marrow (matched sib-
ling: id-SIB, unrelated bone marrow: u-BM) or cord blood (u-CB)
HSCT in a single-center prospective study among pediatric patients.
Between 2006 and 2008, 103 patients were included with a median
age of 5 years (range 0-21); 33 recipients received id-SIB, 33 u-BM
and 37 u-CB grafts. All patients received myelo-ablative condition-
ing and in the unrelated donor setting thymoglobulin (10 mg/kg)
was added from 4 to 2 days before SCT. The number of CD3+ cells
in the graft graft was for uCB 8*10e6 (range 8*10e5 – 4*10e7)/kg, for
id-SIB 4*10e7 (range 1 – 9*10e7)/kg and for u-BM 5 *10e7 (range
1*10e7 – 5*10e8)/kg.
Statistical analysis was performed by Kruskal-Wallis rank sum
tests and Wilcoxon tests with continuity corrections.
Median follow up was 16months (range 1-28); overall survival was
73%. Probability of neutrophil at day 60 did not differ among id-SIB
u-BM and u-CB recipients (median 23 days, range 3-60 after HSCT,
p5 0.092). Overall T-cell (CD3+) reconstitution (first 100 days) was
similar between the 3 groups, but CD8 +T-cell numbers were
higher after id-SIB- and u-BM compared to u-CB HSCT (155 and
309 versus 52 CD8 +T-cells/uL, p5 0.002). Interestingly, NK-
cell and B-cell numbers were significantly higher in u-CB compared
to id-SIB (p5 0.018 and p5 0.0003, resp.) and u-BM recipients
(p5 0.036 and p5 0.0003, resp.) within the first 100 days. On the
long term, in u-CB and id-SIB recipients higher ratios of nave
CD4+ and CD8 T-cells were found (u-CB: 62% and 87%, id-SIB:
55% and 57%) compared to u-BM recipients (30% and 17%) at
1 year after HSCT (p5 0.050 and p5 0.029).
Higher NK- and B-cell numbers early after HSCT indicate
a better proliferative capacity of these u-CB stem cells compared
to id-SIB and u-BM stem cells. We speculate the observed delayed
T-cell reconstitution after u-CB HSCT is caused by a deeper in
vivo depletion using the same dose of thymoglobuline in a setting
of u-CB grafting where the T-cell dose is 1 log lower than an u-BM
graft. Insight in the early immune reconstitution is essential for
the future development of immune-mediated therapies and the
development of optimal graft specific conditioning regimens to
prevent prolonged post-HSCT lymphopenia and the associated
viral complications.55
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Ball, E.2, Castro, J.2, Mulroney, C.2, Curtin, P.2, Maziarz, R.1,
Taplitz, R.2 1Oregon Health and Sciences University, Portland, OR;
2University of California, San Diego, La Jolla, CA
Background: Respiratory virus infections cause significant morbid-
ity in stem cell transplant patients. Novel H1N1 Influenza A (Swine
Origin Influenza A, S-OIV) can result in severe disease in immuno-
compromised hosts.
Methods: Eleven hematopoietic stem cell transplant (HSCT) pa-
tients with influenza A were identified between 4/09 and 7/09.
This retrospective analysis summarizes the patient demographics,
clinical presentation, influenza testing, treatment, and outcome in
these S-OIV-infected HSCT recipients.
Oral Presentations S175Results: Eleven inpatient HSCT recipients were diagnosed with
probable/proven H1N1 influenza in our two centers. Ten had un-
dergone allogeneic HSCT and one had undergone autologous
HSCT. Eight of the 10 allogeneic recipients had either active or
prior GVHD, and 6 were on./5 20 mg of prednisone. The diagno-
sis of S-OIV was made 12 -1000 (median 355) days after HSCT.
Three patients had suspected noscomial infection. Clinical presenta-
tions were diverse, ranging from atypical (febrile/neutropenia with-
out respiratory tract symptoms) to mild (low grade fever and mild
cough) to classic influenza symptoms (high fever, chills, sore throat,
myalgias, cough, headache and nasal congestion). Severity of pre-
senting symptoms did not correlate with outcome; however, hypox-
emia and lower tract disease at diagnosis were predictive of poor
outcomeTwo of 8 rapid tests, 7 of 9 cultures, and 7 of 7 PCR samples
sent were positive for influenza A. Ten patients were treated with an-
tivirals (oseltamivir in 10, + rimantidine in 3). Three patients died
(27%) of progressive pneumonia. Of the two who received antivirals
before death, duration from symptom onset to treatment was a me-
dian of 7.5 days (range 2-15), compared with 7 days (range 1-15) in
those who survived.
Conclusions: S-OIV is a cause of significant morbidity and mor-
tality in HSCT recipients. Patients with cGVHD may be particu-
larly susceptible. Clinical presentation may be subtle and a high
state of vigilance is warranted. The sensitivity of the rapid influenza
test is low. Treatment decisions should be focused on disease risk
and clinical symptoms with confirmation by culture or PCR. Pa-
tients presenting with hypoxemia appeared to have worse out-
comes, and early treatment with antivirals may not abrogate the
severity of disease. Finally, nosocomial infection is a risk, demon-
strating the critical need for rigorous enforcement of infection con-
trol policies.56
CMV-SPECIFIC IMMUNITY AND CMV COMPLICATIONS IN SEROPOSITIVE
HCT RECIPIENTS DEPEND ON DONOR SEROSTATUS
Ugarte-Torres, A.1, Liu, Y.1, Williamson, T.1, Hoegh-Petersen, M.1,
Quinlan, D.2, Roa, L.1, Khan, F.1, Russell, J.A.2, Storek, J.2 1University
of Calgary, Calgary, AB, Canada; 2Alberta Health Services, Calgary, AB,
CanadaComparison of D1R1 and D-R1 patients
Anti-CMV T-cell count
D1 R1
n5 46
D-R1
n5 31 P value
CMV-specific CD4 T cells
per ml (median) Day 28
1.50 0.10 0.048*
Day 56 5.23 0.56 0.005*
Day 84 8.19 1.27 0.001*
Day 180 6.26 0.32 0.002*
Pp65-specific CD8 T cells
per ml (median) Day 28
0.81 0.03 0.04*
Day 56 12.16 1.49 0.03*
Day 84 11.26 2.77 0.11*
Day 180 3.87 2.67 0.60*
Clinical Outcomes D1 R1
n5 177
D-R1
n5 121
P value
CMV reactivation above
threshold for preemptive therapy
(No. of patients with at least one
reactivation, (%))
36 (20.3%) 58 (48.7%) 0.001**
Recurrent CMV reactivation
(No. of patients with at least 2
reactivations, (%))
7 (3.9%) 19 (15.9%) 0.003**
CMV disease (No. of patients, (%)) 5 (2.8%) 16(13.3%) 0.005**
Death 74 (41.8%) 68 (56.2%) 0.038**
* Univariate analysis (Mann-Whitney-Wilcoxon rank-sum test) ** Multi-
variate analysis (Binomial linear model) including the following covari-
ates: HLA-matched sibling graft, significant graft versus host disease
(GVHD) (grade 2-4 acute or extensive chronic GVHD), disease stage,
donor age, length of follow-up.Background: Anti-CMV T-cells are thought to control CMV. In
seropositive recipients of grafts from seropositive donors (D + R+),
both naı¨ve and memory/effector anti-CMV T-cells are transferred
with the graft. In seropositive recipients of grafts from seronegative
donors (D-R+), only naı¨ve anti-CMVT-cells are transferredwith the
graft. We hypothesized that counts of anti-CMV T-cells are higher
in the D +R+ compared to the D-R+ group, and that this leads to
a lower incidence of CMV complications like CMV disease or
CMV reactivation.
Patients and methods: We reviewed charts of 298 seropositive re-
cipients for CMV reactivation (pp65 antigenemia or CMV DNAe-
mia above institutional threshold for starting preemptive therapy),
recurrent CMV reactivation (above the same threshold), CMV dis-
ease, and death due to any cause. In 77 of these patients, we deter-
mined the counts of anti-CMV effector T-cells (producing INFg
upon 18 h stimulation with CMV lysate in case of CD4 T-cells or
pp65 overlapping peptides in case of CD8 T-cells). Conditioning
of all patients included rabbit-anti-human thymocyte globulin
(Thymoglobulin).
Results: The anti-CMV T cell, in particular, CD4 T-cell counts
were higher, and the cumulative incidences of CMV reactivation, re-
current CMV reactivation, CMV disease and death were lower in
D + R+ compared to D-R+ patients.
Conclusion: Compared to D + R+ patients, D-R+ have lower
counts of anti-CMV T-cells. This appears to translate into a higher
risk of CMV reactivation, CMV disease and lower survival. New
strategies to avoid CMV complications need to be explored for
D-R+ patients, eg, donor vaccination pre-transplant or infusion of
anti-CMV T-cells post-transplant.LATE EFFECTS/QUALITY OF LIFE
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HEALTH BEHAVIORS AND CANCER SCREENING PRACTICES IN LONG-
TERM SURVIVORS OF HEMATOPOIETIC CELL TRANSPLANTATION
(HCT): A REPORT FROM THE BONE MARROW TRANSPLANT SURVIVOR
STUDY (BMTSS)
Armenian, S.H.1, Sun, C.1, Francisco, L.1, Arora, M.2, Baker, K.S.3,
Forman, S.J.1, Bhatia, S.1 1City of Hope National Medical Center, CA;
2University of Minnesota, Minneapolis, MN; 3Fred Hutchinson Cancer
Research Center, Seattle, WA
Background: Patients undergoing HCT are at increased of risk
chronic health conditions, including second malignant neoplasms
and cardiovascular disease. Little is known about health behaviors
and cancer screening practices among HCT survivors that could
moderate the risk of these conditions.
Methods: The BMTSS examined health behaviors and cancer
screening practices in individuals who underwent HCT at City of
Hope or University of Minnesota between 1976 and 1998, and sur-
vived 2+ years. Responses from a mailed questionnaire were com-
pared to those obtained from sibling controls. Health behavior was
deemed high-risk if an individual was a current smoker or if they re-
ported risky alcohol intake ($4 drinks/day [males], $3 drinks/day
[females]) on days of alcohol consumption. Questions regarding can-
cer screening practices were tailored to assess adherence to American
Cancer Society guidelines for breast and cervical (females) and testic-
ular (males) cancers.
Results: The study included 1040 survivors: 42.7% underwent al-
logeneic HCT; 43.8% were female; median time from HCT was
7.4 years (range 2.0-27.7 years). Median age at study participation
was 43.8 years (range 18.3-73.0 years) for survivors and 45.2 years
(range 19.3-78.8 years) for siblings (N5 309). Survivors reported
significantly lower rates of high-risk behavior (14.6% v 21.0%;
p\0.01) compared to controls. Adjustment for patient demo-
graphics, SES, diagnosis, HCT-related exposures, and presence
of chronic medical conditions, revealed younger age (\35 years)
at study participation (Odds Ratio [OR]5 5.0; p\0.01), being un-
insured (OR 2.0; p5 0.02), and lower education (\college:
OR5 2.3; p\0.01) to be significantly associated with high-risk be-
havior. HCT survivors reported similar cancer screening practices
when compared to gender-matched sibling controls: Females–
regular self-breast examination (28.9% v 27.0%; p5 0.6), clinical
breast examination (88.4% v 91.3%; p5 0.3), pap smears (85.5%
